Trial Profile
A Phase 2 Study of AZD2171 in Patients With Advanced Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 24 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 10 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2007 Status changed from recruiting to in progress.